Tilray Brands, Inc. - Common Stock (NQ:TLRY)

2.530 -0.110 (-4.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tilray Brands, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Canopy Growth vs. Tilray Brands: Quarterly Revenue Scale and Consistency in Cannabis ↗

October 30, 2026

Tilray commands a 4x revenue advantage, but Canopy's latest quarter hints at momentum—here's what the data reveals about their competitive positioning.

Via The Motley Fool

Topics Cannabis Economy

Down 70% in 2026, Has Tilray's Stock Finally Bottomed Out? ↗

October 27, 2026

The cannabis stock has generated nearly $1 billion in revenue over the past year, and its market cap is less than half of that.

Via The Motley Fool

Topics Cannabis

Tilray Now Sells More Beer Than Cannabis. Here's Why That Might Be Good News for Investors. ↗

October 25, 2026

Tilray's transformation is still ongoing, but it just reached a critical milestone.

Via The Motley Fool

Topics Cannabis Law Enforcement

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful ↗

October 20, 2026

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than the headline suggests.

Via The Motley Fool

Topics Cannabis Retirement

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026? ↗

October 15, 2026

The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable. Canopy is narrowing losses and targeting positive EBITDA by...

Via The Motley Fool

Topics Cannabis

3 Huge Red Flags From Tilray's Q1 Earnings Report ↗

October 12, 2026

The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.

Via The Motley Fool

Topics Cannabis

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 10, 2026

Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.

Via The Motley Fool

Topics Cannabis

3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices ↗

October 10, 2026

Tilray's stock isn't the bargain it appears to be at first.

Via The Motley Fool

Topics Cannabis

Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform ↗

October 09, 2026

Tilray Brands' fiscal Q1 2027 results show beverage revenue up 82% and European medical cannabis growth offsetting weaker Canadian sales, reducing reliance on U.S. federal rescheduling.

Via MarketBeat

Topics Cannabis

Tilray (TLRY) Q1 2027 Earnings Call Transcript ↗

October 08, 2026

BrewDog profitability and record revenue signal diversified growth momentum.

Via The Motley Fool

Topics Cannabis Earnings

Tilray Brands Q1 Earnings Call Highlights ↗

October 08, 2026

Tilray Brands (NASDAQ:TLRY) reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while...

Via MarketBeat

Topics Cannabis Earnings

Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation ↗

October 06, 2026

Curaleaf has raised its hostile bid for Aurora Cannabis to $5 per share as Schedule III tax relief fuels cannabis M&A, with Tilray's Oct. 8 earnings seen as a sector barometer.

Via MarketBeat

Topics Cannabis ETFs

Tilray Brands: Is the Stock a Buy at Less Than $4? ↗

October 06, 2026

The stock is down big this year, but that doesn't mean it's overdue for a rally.

Via The Motley Fool

Topics Cannabis

Tilray Is Down 57% in 2026. Here's What History Says About Buying Pot Stocks at the Bottom ↗

October 02, 2026

Is Tilray's situation hopeless?

Via The Motley Fool

Topics Cannabis ETFs

Should You Buy Tilray Brands Stock Before Oct. 8? ↗

September 28, 2026

The cannabis company is set to report its earnings early next month.

Via The Motley Fool

Topics Cannabis

Should You Buy Tilray Stock Under $5? ↗

September 23, 2026

There's a reason why shares keep tumbling, despite signs of a turnaround.

Via The Motley Fool

Topics Cannabis

Will Tilray Brands Stock Take Off Before the End of 2026? ↗

September 21, 2026

The cannabis stock has been struggling badly this year, but there could be a catalyst up ahead.

Via The Motley Fool

Topics Cannabis

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock ↗

September 15, 2026

The cannabis stock has moved quickly in the past when there's been talk of marijuana reform.

Via The Motley Fool

Topics Cannabis

Trump's Marijuana Rescheduling Push Is Back in Focus. Is Tilray Stock Finally a Buy? ↗

September 15, 2026

The Tilray bull case is getting stronger without U.S. legalization.

Via The Motley Fool

Topics Cannabis Government Lawsuit

Tilray Trades Below $5 With Record Fiscal Revenue on the Books. What's Holding the Stock Back? ↗

September 12, 2026

Tilray Brands has moved beyond marijuana, turning itself into a diversified brand manager.

Via The Motley Fool

Topics Cannabis

Should You Buy Canopy Growth Stock on the Rebound? ↗

September 05, 2026

Canopy Growth benefited from growth across all its divisions in the first quarter of fiscal 2027, but does that make it a worthwhile investment?

Via The Motley Fool

Topics Cannabis

Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again? ↗

September 02, 2026

Don't expect a rebound anytime soon.

Via The Motley Fool

Topics Cannabis

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands? ↗

September 02, 2026

The Canadian cannabis companies are both seeing strong growth, but one is a better buy right now.

Via The Motley Fool

Topics Cannabis

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying? ↗

August 23, 2026

Recent results and legalization progress aren't the game changers you'd think they'd be for this cannabis stock.

Via The Motley Fool

Topics Cannabis

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners. ↗

August 21, 2026

After a huge gold rush, the marijuana sector stumbled, and now consolidation is gaining momentum.

Via The Motley Fool

Topics Cannabis

Tilray Brands Expects to Hit a Major Milestone for the Current Fiscal Year: $1 Billion in Annual Revenue. Here's How it Plans to Get There ↗

August 10, 2026

The cannabis stock has struggled despite Tilray achieving solid growth in its most recent fiscal year.

Via The Motley Fool

Topics Cannabis

Tilray Brands Posted Record Numbers for Fiscal 2026. Here's Why That's Not Enough to Make the Stock a Buy ↗

August 04, 2026

The company's true organic growth is difficult to gauge given its high dependency on acquisitions.

Via The Motley Fool

Topics Cannabis

The Surprising Part of Tilray's Business That Drove Most of Its Growth Last Year ↗

August 03, 2026

Tilray's distribution segment was the only one that generated double-digit growth in its most recent fiscal year.

Via The Motley Fool

Topics Cannabis

Tilray Brands (TLRY) Stock Is Trending: Here's What You Should Know ↗

July 29, 2026

Tilray Brands shares jumped 2.23% after hours as quarterly revenue beat estimates, despite earnings per share missing expectations.

Via Benzinga

Tilray Brands Q4 Earnings Call Highlights ↗

July 28, 2026

Tilray Brands (NASDAQ:TLRY) reported record fiscal 2026 revenue and adjusted EBITDA, supported by growth in international cannabis, pharmaceutical distribution, wellness and the fourth-quarter...

Via MarketBeat

Topics Cannabis Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.